Source: MarketScreener

Sierra: Sierra Oncology : Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

( - Data presented at the 25th European Hematology Association Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib -- Long-term tolerability facilitates sustained dose intensity and prolonged clinical activity; longest ongoing treatment now extends to 10 years - VANCOUVER,...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Stephen Dilly's photo - President & CEO of Sierra Oncology, Inc.

President & CEO

Stephen Dilly

CEO Approval Rating


Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more